Scholarlink

Background <p>The clinical presentation of melanoma of unknown primary (MUP) and its treatment patterns remain incompletely characterized.</p> Methods <p>GEM1801 is a prospective, observational study in Spain enrolling patients with advanced melanoma. This analysis describes the clinical features and outcomes of patients with MUP.</p> Results <p>From August 2018 to December 2022, 893 evaluable patients were enrolled, of whom 133 (14.9%) had MUP. Median age was 63&#xa0;years (range 24–93); 81 (60.9%) were men; 117 (88.0%) had distant metastases; lactate dehydrogenase (LDH) was elevated in 50 (37.6%); and 79 (54.9%) had BRAF-mutated tumors. Compared with patients with a known primary, immunotherapy was prescribed less frequently (adjuvant: 15.5% vs 27.2%, <i>p</i> = 0.007; first-line metastatic: 53.6% vs 64.0%, <i>p</i> = 0.039). Median progression-free survival (PFS) was 18.9&#xa0;months (95% CI: 4.4-NR), 13.3&#xa0;months (95% CI: 7.1–27.5), and 6.7&#xa0;months (95% CI: 3.5-NR), and median overall survival (OS) was 24.9&#xa0;months (95% CI: 24.1-NR), 13.9&#xa0;months (95% CI: 8.3-NR), and 17.9&#xa0;months (95% CI: 9.6-NR) in patients with BRAF-mutated tumors treated with immunotherapy, BRAF-mutated tumors treated with targeted therapy, and BRAF-wild-type tumors treated with immunotherapy, respectively.</p> Conclusions <p>In Spain, MUP is characterized by multi-organ involvement and frequent brain metastases and was associated with worse outcomes than the overall melanoma cohort. A diagnosis of MUP appears to influence treatment allocation, particularly regarding immunotherapy. When stratified by BRAF status and treatment type, no survival differences were observed between MUP and melanoma of known primary, except for OS among patients with MUP and BRAF-mutated tumors treated with immunotherapy.</p> Clinical trial identification <p>clinicaltrials.gov: NCT03605771.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801

  • 期刊论文

  • 发表日期：

    2025年12月20日

查看全文
  • Pablo Cerezuela-Fuentes,
  • Antonio Piñero-Madrona,
  • Eva Muñoz-Couselo,
  • José Luis Manzano,
  • Miguel-Ángel Berciano-Guerrero,
  • Margarita Majem,
  • Enrique Espinosa,
  • Ainara Soria,
  • Pablo Ayala de Miguel,
  • Almudena García Castaño,
  • Guillermo Crespo,
  • Lourdes Gutiérrez Sanz,
  • Carlos Aguado de la Rosa,
  • Luis Antonio Fernández-Morales,
  • Teresa Puértolas,
  • Joaquín Fra Rodríguez,
  • María Rodríguez de la Borbolla,
  • Lorena Bellido,
  • Rafael López Castro,
  • Victor Navarro Pérez,
  • Francisco Ramón García Arroyo,
  • José Carlos Villa Guzmán,
  • Begoña Campos Balea,
  • Berta Hernández,
  • Salvador Martín Algarra,
  • Iván Márquez-Rodas

摘要

Background

The clinical presentation of melanoma of unknown primary (MUP) and its treatment patterns remain incompletely characterized.

Methods

GEM1801 is a prospective, observational study in Spain enrolling patients with advanced melanoma. This analysis describes the clinical features and outcomes of patients with MUP.

Results

From August 2018 to December 2022, 893 evaluable patients were enrolled, of whom 133 (14.9%) had MUP. Median age was 63 years (range 24–93); 81 (60.9%) were men; 117 (88.0%) had distant metastases; lactate dehydrogenase (LDH) was elevated in 50 (37.6%); and 79 (54.9%) had BRAF-mutated tumors. Compared with patients with a known primary, immunotherapy was prescribed less frequently (adjuvant: 15.5% vs 27.2%, p = 0.007; first-line metastatic: 53.6% vs 64.0%, p = 0.039). Median progression-free survival (PFS) was 18.9 months (95% CI: 4.4-NR), 13.3 months (95% CI: 7.1–27.5), and 6.7 months (95% CI: 3.5-NR), and median overall survival (OS) was 24.9 months (95% CI: 24.1-NR), 13.9 months (95% CI: 8.3-NR), and 17.9 months (95% CI: 9.6-NR) in patients with BRAF-mutated tumors treated with immunotherapy, BRAF-mutated tumors treated with targeted therapy, and BRAF-wild-type tumors treated with immunotherapy, respectively.

Conclusions

In Spain, MUP is characterized by multi-organ involvement and frequent brain metastases and was associated with worse outcomes than the overall melanoma cohort. A diagnosis of MUP appears to influence treatment allocation, particularly regarding immunotherapy. When stratified by BRAF status and treatment type, no survival differences were observed between MUP and melanoma of known primary, except for OS among patients with MUP and BRAF-mutated tumors treated with immunotherapy.

Clinical trial identification

clinicaltrials.gov: NCT03605771.